Pharmaceuticals

Yatai pharm

Yatai Pharm released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 59.58 M, actual EPS CNY -0.0035

Yatai Pharm released FY2025 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 94.83 M, actual EPS CNY -0.0011

Yatai Pharm released FY2025 Annual Earnings on April 24 After-Market BJT, Actual Revenue: CNY 323.14 M, Actual EPS: CNY 0.13

Yatai Pharm FY2026 Q1 Earnings Release on April 25 After-Market (BJT)

Yatai Pharm FY2025 Annual Earnings Release on April 25, 2026 After-Market BJT

Yatai Pharm released FY2025 Q3 earnings on October 28 After-Market (BJT), actual revenue CNY 76.23 M, actual EPS CNY -0.0111

Yatai Pharm released FY2025 9 Months Earnings on October 28 After-Market (BJT), actual revenue CNY 228.31 M, actual EPS CNY 0.1271

Yatai Pharm to Release FY2025 Q3 Earnings on October 29 After-Market (BJT)

Yatai Pharm released FY2025 Semi-Annual Earnings on August 29 Pre-Market (BJT), Actual Revenue: CNY 152.07M, Actual EPS: CNY 0.14

Yatai Pharm released FY2025 Q2 earnings on August 29 Pre-Market (BJT), actual revenue CNY 87.52 M, actual EPS CNY 0.1487

Yatai Pharm to Release FY2025 Semi-Annual Earnings on August 30, 2025, BJT

Asia Pacific Pharmaceutical Reports Q1-Q2 2025 Net Profit Forecast to Increase by 1700%

AP Asia Pharmaceutical's Spironolactone Tablets Receive Consistency Evaluation Acceptance

Asia Pacific Pharmaceutical's ESG Rating Revealed

AP Asia Pharma's registered capital increased to 740 million yuan

Asia Pacific Pharma Reports Widening Net Loss in Q1 2025

Yatai Pharm released FY2025 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 64.55 M, actual EPS CNY -0.0105

Asia Pacific Pharmaceutical's Acyclovir for Injection Passes Consistency Evaluation

Yatai Pharm released FY2024 earnings on April 24 After-Market (BJT), actual revenue CNY 405.17 M, actual EPS CNY 0.05

Yatai Pharm released FY2024 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 98.34 M, actual EPS CNY 0.0425

002370

Yatai Pharm announced that the cumulative deviation of the stock price increase on October 31 and November 3, 2025, exceeded 20%, indicating abnormal fluctuations. The controlling shareholder, Fubon Group, intends to transfer 14.61% of its shares, and the actual controller will change to Qiu Zhongxun. The company also plans to conduct a private placement to Xinghao Holdings, which constitutes a related party transaction. Both matters carry uncertainties, and investors are reminded to pay attention to risks

Zhitong

Yatai Pharm: The cumulative deviation of the stock price increase over the past two days exceeds 20%, warning of risks

300878

300497

002940

688336

A-share innovative drug concept stocks are active again, Sunshine Guojian Pharmaceutical rose over 10% to a new high, Yatai Pharm had two consecutive limit-ups, WECOME rose over 10%, and Baicheng Pharmaceutical, ALK, and Fushine followed suit

WECOME

Fushine

Sunshine Guojian Pharmaceutical

According to the Zhitong Finance APP, Yatai Pharm released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 228 million yuan, a year-on-year decrease of 25.59%. The net profit attributable to shareholders of the listed company was 97.195 million yuan, a year-on-year increase of 2909.49%. The net loss attributable to shareholders of the listed company, after deducting non-recurring gains and losses, was 56.5853 million yuan

Yatai Pharm released its performance for the first three quarters, with a net profit attributable to the parent company of 97.195 million yuan, a year-on-year increase of 2909.49%

Yatai Pharm announced that its controlling shareholder will change to Zhejiang Xinghao Holdings, and the actual controller will change to Qiu Zhongxun. The company plans to issue no more than 137 million shares to specific targets, with an issue price of 5.11 yuan per share, raising a total of no more than 700 million yuan, all of which will be used for new drug research and development. The stock will resume trading on October 14, 2025

The actual controller of Yatai Pharm will change to Qiu Zhongxun, and trading will resume on October 14

Yatai Pharm announced that the company's controlling shareholder Fubon Group and its concerted party Hangu Investment have signed a Share Transfer Agreement with Xinghao Holdings and Xingchen Investment. Fubon Group and Hangu Investment plan to transfer 14.61% of the company's shares, totaling 109 million shares, through an agreement transfer. The transfer price is 8.26 yuan per share, with a total amount of 900 million yuan. If this transaction is ultimately implemented, the company's controlling shareholder will change from Fubon Group to Xinghao Holdings, and the actual controller of the company will change from the management team composed of Song Hanping, Fu Cai, and Hu Zhenghui to Qiu Zhongxun

Yatai Pharm: Signed a share transfer agreement, control rights are expected to change

Yatai Pharm is planning a change of control, which may lead to a change in the controlling shareholder and actual controller. The company's stock has been suspended from trading since September 29, expected to last no more than 2 trading days. As related work is still in progress, the stock will continue to be suspended from trading starting October 9, expected to last no more than 3 trading days. The company will fulfill its information disclosure obligations as required and remind investors to pay attention to risks

Yatai Pharm plans to change control, stock suspension will not exceed 3 days

600735

On September 29th, 8 companies were temporarily suspended: HIKING, IM Motors, *ST Gao Hong, Duorui Pharmaceutical, Yatai pharm, Yidao Information, Zhonghuan Environmental Protection, and Meichen Technology. 3 companies resumed trading: Galaxy Magnetic, Guanzhong Ecology, and New Dazheng

HIKING

Summary of Trading Suspension and Resumption Before Market Open on September 29

According to the Zhitong Finance APP, Yatai Pharm released its semi-annual report for 2025, reporting an operating income of 152 million yuan, a year-on-year decrease of 31.48%. The net profit attributable to shareholders of the listed company was 105 million yuan, a year-on-year increase of 1820.97%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 48.8622 million yuan, a year-on-year increase of 524.31%. The basic earnings per share were 0.14 yuan

Yatai Pharm released its performance for the first half of the year, with a net profit attributable to the parent company of 105 million yuan, an increase of 1820.97%

301678

301357

603280

This week, 71 stocks had a turnover rate exceeding 100%, with North Long Dragon ranking first at a weekly turnover rate of 257.92%. Fujian South Highway Machinery and C Han Gao both had turnover rates exceeding 200%. There were many stocks in the electronics, machinery equipment, and pharmaceutical biology industries. In terms of price increase, stocks such as Fujian South Highway Machinery, Tianfu Culture & Tourism, HENGHUI Technology, Longyang Electronics, and Yatai Pharm all saw price increases exceeding 30% this week

HENGHUI Technology

North Long Dragon

Fujian South Highway Machinery

The list of the top ten active stocks this week has been released, with 71 stocks having a cumulative turnover rate exceeding 100%

600481

002287

300724

The A-share market experienced a rise and then a fall throughout the day, with the three major indices slightly declining. Pharmaceutical stocks continued to show strength, with CheezhengTTM, Yatai pharm, and several other stocks hitting the daily limit. The AI application sector remained active, with Qidi Design and Zhengzhong Design also reaching the limit. The photovoltaic sector collectively rebounded, with S.C and Shuangliang Eco-Energy hitting the daily limit. More stocks rose than fell, with over 3,300 stocks in the Shanghai, Shenzhen, and Beijing markets in the green. Today's trading volume was 1.62 trillion yuan, a decrease of over 340 billion compared to the previous day. By the close, the Shanghai Composite Index fell by 0.37%, the Shenzhen Component Index fell by 0.17%, and the ChiNext Index fell by 0.24%

Wallstreetcn

Shuangliang Eco-Energy

CheezhengTTM

A-shares closing: Three major indices slightly declined, while the pharmaceutical and photovoltaic sectors strengthened against the trend

Yatai pharm(002370.SZ)